

Ref: ASCL/SEC/2023-24/61

March 27, 2024

1. To,

The General Manager

Department of Corporate Services

**BSE Limited** 

1st Floor, New Trading Ring

Rotunda Building, P. J. Tower

Dalal Street, Fort

Mumbai - 400 001

BSE Scrip Code: 532853

2. To,

The General Manager (Listing)

National Stock Exchange of India Ltd

5th Floor, Exchange Plaza

Plot No. C/1, G Block

Bandra - Kurla Complex

Bandra (East)

Mumbai - 400 051

**NSE Trading Symbol: ASAHISONG** 

SUB: DISCLOSURE / INTIMATION OF ACQUISITION OF STAKE

REF: REGULATION 30 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE

REQUIREMENTS) REGULATIONS, 2015 ("SEBI LISTING REGUALTIONS")

Dear Sirs,

We wish to inform you that Asahi Songwon Colors Limited ("the **Company**") has acquired remaining 6,60,000 shares i.e. 22% stake in Atlas Life Sciences Private Limited ("**ALSPL**") on March 26, 2024.

Pursuant to said acquisition of remaining 22% stake in ALSPL, the Company's shareholding in ALSPL has increased from 78% (pre-acquisition) to 100% (post acquisition) and ALSPL became Wholly Owned Subsidiary (WOS) of the Company.

ALSPL is one of the leading manufacturers of Active Pharmaceutical Ingredients (API) and Bulk Drugs, with dominant position in Pregabalin (PG) and 4 other API's and one intermediate (R-CMH for PG).



Tele: 91-79 6832 5000 • Fax: 91-79 6832 5099 • Web Site: www.asahisongwon.com





The disclosures pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 is attached as per "Annexure - A".

Kindly take the above information on your records.

Thanking you,

Yours faithfully, For, **ASAHI SONGWON COLORS LIMITED** 

JOSEPH SAJI VARGHESE

Digitally signed by JOSEPH SAJI VARGHESE Date: 2024.03.27 13:22:24 +05'30'

SAJI JOSEPH Company Secretary and Compliance Officer

Encl: As above









## Annexure - A

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023.

- a) Name of the target entity, i) Name of the Target: details in brief such as size, turnover etc
- Name of the Target: Atlas Life Sciences
  Private Limited ("ALSPL")
  - ii) Business of the Target: ALSPL is one of the leading manufacturers of Active Pharmaceutical Ingredients (API) and Bulk Drugs. ALSPL product portfolio includes Pregabalin, R-Compund, Phenylephrine HCL, Gliclazide, Amisulpride and Levosulpiride.
  - iii) Financial details as per the audited financial statements for the Financial Year 2022-2023:

Turnover: Rs. 51,041.07 Lakhs

Earning before interest, taxes, depreciation and amortization (EBITDA): Rs. (1,774.17) lakhs.

b) Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? if yes, nature of interest and details thereof and whether the same is done at "arms-length";

The acquisition falls within related party transaction in term of regulation 2(zc) of the SEBI Listing Regulations.

The promoter/promoter group companies of the Company do not have any interest in the entity being acquired.

## Asahi Songwon Colors Ltd.

CIN: L24222GJ1990PLC014789

Regd. Office: "Asahi House", 20, Times Corporate Park, Thaltej – Shilaj Road, Thaltej, Ahmedabad – 380 059, Gujarat, India.

Tele: 91-79 6832 5000 • Fax: 91-79 6832 5099 • Web Site: www.asahisongwon.com







c)	Industry to which the entity	Manufacturing of Active Pharmaceutical
	being acquired belongs;	Ingredient (API) and Bulk Drugs.
d)	Objects and effects of	Asahi Songwon Colors Limited ("Company")
	acquisition (including but	in order to add a new growth lever and to
	not limited to, disclosure of	create significant value by leveraging
	reasons for acquisition of	combined capabilities and unlock synergies
	target entity, if its business	entered into API and Bulk Drug business.
	is outside the main line of	The API business of ALSPL has diversified
	business of the listed	portfolio of 6+ products with several of them
	entity);	in R&D product pipeline.
e)	Brief details of any	Not applicable
	government or regulatory	,
	approvals required for the	
	acquisition;	4
f)	Indicative time of	The acquisition of shares under first tranche
	completion of the	i.e. 78% stake in ALSPL was completed on
	acquisition;	April 18, 2022 in terms of Share Purchase
		Agreement dated April 18, 2022 and the
		Balance 22% stake in ALSPL is Acquired on
		March 26, 2024.
		Pursuant to said acquisition of remaining
	e)	22% stake in ALSPL, 100% acquisition has
	Water of sensidentian	been completed.  Cash Consideration. The acquisition of
g)	Nature of consideration - whether cash consideration	Cash Consideration. The acquisition of shares under first tranche i.e. 23,40,000
		shares of ALSPL representing 78% stake in
	or share swap and details of the same;	ALSPL was completed on April 18, 2022 for
h)		a consideration of INR 4800 Lakhs.
11)	price at which the shares	a consideration of first 1000 Bassis.
	are acquired;	Balance 6,60,000 shares representing 22%
il	Percentage of shareholding/	stake in ALSPL is acquired in single tranche
-,	control acquired and / or	on March 26, 2024 for a consideration of Rs.
	number of shares acquired	INR 965 Lakhs.
j)	Brief background about the	i) Line of business:
3,	entity acquired in terms of	ALSPL is one of the leading manufacturers of
	products/line of business	Active Pharmaceutical Ingredients (API) and
	acquired, date of	Bulk Drugs. The Companies product portfolio
	incorporation, history of	includes Pregabalin, R-Compund,

## Asahi Songwon Colors Ltd.

CIN: L24222GJ1990PLC014789

Regd. Office: "Asahi House", 20, Times Corporate Park, Thaltej – Shilaj Road,
Thaltej, Ahmedabad – 380 059, Gujarat, India.
Tele: 91-79 6832 5000 • Fax: 91-79 6832 5099 • Web Site: www.asahisongwon.com





last years turnover, which the country in acquired entity has presence and any other significant information (in brief)

Phenylephrine HCL, Gliclazide, Amisulpride and Levosulpiride.

Date of Incorporation: ALSPL is incorporated on April 22, 2004 in India.

iii) Turnover of last three financial years

Financial Year	Turnover (Amount in Lakhs)
FY 2022-23	13,589.49
FY 2021-22	14,845.52
FY 2020-21	10,929.00

For, ASAHI SONGWON COLORS LIMITED

**JOSEPH SAJI** 

Digitally signed by JOSEPH SAJI VARGHESE

**VARGHESE** 

Date: 2024.03.27 13:23:20 +05'30'

SAJI JOSEPH

Company Secretary and Compliance Officer

CIN: L24222GJ1990PLC014789

Regd. Office: "Asahi House", 20, Times Corporate Park, Thaltej - Shilaj Road, Thaltej, Ahmedabad - 380 059, Gujarat, India.

Tele: 91-79 6832 5000 • Fax: 91-79 6832 5099 • Web Site: www.asahisongwon.com

